Life Science News

lobe sciences ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has filed a provisional patent for the preparation and use of its proprietary and stable psilocin related compounds.

Philip Young, CEO of Lobe Sciences stated, "Our patent portfolio now consists of multiple patent filings for the use and delivery of psilocybin, psilocin analogues and N-Acetyl Cysteine (NAC) as well as a new patent that covers the uses and preparation of multiple proprietary stable forms of the psilocin molecule. The Company is actively pursuing drug development programs using two initial proprietary psilocin analogues. L-130, targeting neurologic conditions such as severe anxiety, Post Traumatic Stress Disorder (PTSD), as well as other brain traumas. L-131, a second new chemical entity related to psilocin and covered in the recently filed patent application is a drug candidate for a second neurological disorder affecting children."

Lobe is focused on delivering a patient friendly treatment plan focused on delivering our therapeutics at patients' homes, in their physician's offices or in the Emergency Department in a local hospital setting. Delivering a non-hallucinatory dose of our proprietary compounds, over several days should enable patients and their personal doctors the opportunity to maintain their normal routine while receiving treatment, allowing significantly more people access to this new therapeutic approach.

About lobe sciences ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

lobe sciences ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

NEITHER THE CSE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

This does not constitute an offer to sell or a solicitation of offers to buy any securities.

Disclaimer for Forward Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, and the development of innovative devices and delivery mechanisms to improve mental health and wellness, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment;, that the Company's drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company's corporate goals and objectives; and other risk factors detailed in the Company's continuous disclosure filings from time to time, as available under the Company's profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/131257

News Provided by Newsfile via QuoteMedia

LOBE:CNX
Lobe Sciences

Lobe Sciences


Keep reading...Show less
Lobe Sciences Enters into an Exclusive Agreement With iNGENu to Conduct Clinical Trials in Australia

Lobe Sciences Enters into an Exclusive Agreement With iNGENu to Conduct Clinical Trials in Australia

lobe sciences ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has entered into an exclusive agreement with iNGENū Pty Ltd. ("iNGENū"), an Australian based Contract Research Organization (CRO), to design and conduct three or more clinical trials evaluating Lobe's proprietary psilocin analogues L-130 or L-131.

Philip Young, CEO of Lobe Sciences stated, "We are extremely happy to have partnered with iNGENū as we move our proprietary stable psilocin products into human clinical trials. iNGENū is an industry leading, full service CRO providing end-to-end services for companies developing cannabinoid and psychedelic drugs. We evaluated CRO's in multiple geographies and chose iNGENu as their core values match ours and our commitment to discovering transformational therapies for multiple Central Nervous System diseases and trauma."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Lobe Sciences Ltd. Announces Regulatory and Clinical Development Plans For 2022 and Early 2023

Lobe Sciences Ltd. Announces Regulatory and Clinical Development Plans For 2022 and Early 2023

lobe sciences ltd. (CSE: LOBE) (OTCQB: LOBED) ("Lobe" or the "Company"), a Canadian Biotechnology company committed to discovering and developing psychedelic derived medicines today announced it has developed its initial Phase 1 study plan intended to demonstrate the safety and appropriate dosing range for its proprietary new chemical entity; L-130. It is also announcing the acquisition of a second new chemical entity, L-131, which is expected to enter preclinical toxicity trials later this year or early in 2023.

Philip Young, CEO of Lobe Sciences stated, "L-130 and L-131 are unique synthetic analogues of psilocin, the active metabolite of natural psilocybin, a substance extracted from a species of psychedelic mushroom. We have designed a regulatory development strategy to support the registration of these new chemical entities with the U.S. Food and Drug Administration (FDA). Our initial focus for our clinical program is to treat neurologic disorders, such as severe anxiety and we are in the final stages of selecting a contract research organization to support these studies."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Lobe Sciences Ltd. and Clearway Global LLC Enter into a Development Agreement to Manage Lobe Sciences Ltd.'s Global Regulatory and Development Strategy and its Implementation

Lobe Sciences Ltd. and Clearway Global LLC Enter into a Development Agreement to Manage Lobe Sciences Ltd.'s Global Regulatory and Development Strategy and its Implementation

lobe sciences ltd. (CSE: LOBE) (OTCQB: LOBED) ("Lobe" or the "Company"), a Canadian Biopsychedelics company committed to discovering and developing psychedelic inspired medicines for the improvement of neurologic, brain and mental health disorders, today announced an exclusive agreement with Clearway Global LLC ("Clearway").

Philip Young, CEO of Lobe stated, "We are pleased to have the opportunity to team up with the Clearway network and in particular with Dr. Fred Sancilio, a global expert in drug development and strategic planning. Dr. Sancilio brings over 40 years of pharmaceutical experience to our program and has a track record of success that is unmatched".

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Lobe Sciences Announces Roadmap for Remainder of 2022 and Early 2023

Lobe Sciences Announces Roadmap for Remainder of 2022 and Early 2023

lobe sciences ltd. (CSE: LOBE) (OTCQB: LOBED) ("Lobe" or the "Company"), a Canadian Biopharmaceutical Company committed to discovering and developing psychedelic inspired medicines for the improvement of neurologic, brain and mental health disorders is reporting its roadmap for the remainder of 2022 and into 2023.

Philip Young CEO and Director stated, "I am happy to report that we have made significant progress since our last update in Q3 last year. The next 12 months will see the culmination of investments we've made in the development of therapeutics to treat neurological diseases such as Post Traumatic Stress Disorder (PTSD) and mild Traumatic Brain Injury (mTBI). Preclinical models have shown statistically significant results in the treatment of PTSD and mTBI caused by induced trauma. The combinations of psilocybin with n-acetyl cysteine (NAC) delivered superior results compared to either drug alone. Our patent pending combination therapy may allow for the use of sub-psychedelic dosing while retaining efficacy on these and other disorders."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Lobe Sciences Ltd Announces Change in Record Date of Share Consolidation

Lobe Sciences Ltd Announces Change in Record Date of Share Consolidation

lobe sciences ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") announces that further to the Company's June 6, 2022, news release, the record date for the six for one consolidation has been adjusted to June 10, 2022.

The Canadian Securities Exchange has published a bulletin confirming that trading will remain halted June 9, 2022, and resume trading on a consolidated basis on Friday, June 10.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Awakn Life Sciences Signs Second Licensing Partnership Agreement and Expands Commercial Operations Into Canada

Awakn Life Sciences Signs Second Licensing Partnership Agreement and Expands Commercial Operations Into Canada

Licensing Partnership with Wellbeings(R) marks entry into Canadian addiction treatment and relapse prevention market

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today it has signed its first licensing partnership agreement in Canada with Wellbeings® Pain Management and Dependency Clinic (Wellbeings). The agreement will enable Ontario based Wellbeings®, who are focused on multi-disciplinary, evidence based, best-practice, patient centred care, to treat their patients with Awakn's proprietary ketamine-assisted therapy for the treatment of AUD as a co-morbidity for pain.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Psychedelics Stocks to Watch (Updated 2022)

Psychedelics Stocks to Watch (Updated 2022)

The small-cap market has been invaded by a flurry of psychedelics stocks to watch thanks to new company launches. Investors now have a variety of options for taking a run in the shroom stocks space.

In an effort to expand the capabilities of the medical field, companies are starting to investigate the potential of psychedelic medicines and are looking to raise capital in the public market.

While this industry is still in its early stages, the promising potential of psychedelic medicine drug products has attracted the interest of savvy investors eager for an emerging investment opportunity.

Keep reading...Show less
Love Pharma Announces Strategic Acquisition of Doc Hygiene Pharmaceuticals Inc.

Love Pharma Announces Strategic Acquisition of Doc Hygiene Pharmaceuticals Inc.

Love Pharma Inc. ("LOVE" or the "Company") (CSE:LUV)(FSE:G1Q0) is pleased to announce that it has entered into a definitive agreement (the "Agreement") to acquire Doc Hygiene Pharmaceuticals Inc. ("Doc Hygiene") for aggregate consideration of US$300,000 (the "Acquisition"). Doc Hygiene has a premium hygiene product line and brand for hygiene and sanitizing needs and a robust e-commerce platform for products and SKU's

"We are thrilled to announce the acquisition of Doc Hygiene," said Zach Stadnyk, CEO of LOVE. "We are extremely excited about Doc Hygiene's growth potential in the years ahead and firmly believe it will provide a parallel revenue stream to our existing business in over-the-counter products. Through this acquisition, the company now has a strong online e-commerce platform that will strengthen its product offering and ease of operational online sales from both a B2C and B2B standpoint."

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Health Canada Grants MDMA Production and Distribution Amendment to Optimi Health

Health Canada Grants MDMA Production and Distribution Amendment to Optimi Health

Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a Canadian-based company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms for transformational human experiences, has received permission from Health Canada to manufacture and distribute additional psychedelic substances, most notably MDMA, under the amended terms outlined in its June 20, 2022 application to Health Canada.

Under the leadership of Chief Science Officer Justin Kirkland, Optimi will now act as wholesale supplier of MDMA and other synthetic psychedelic compounds to approved researchers and drug developers.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
 Revitalist Partners with Awakn Life Sciences as First Licensee in the United States to begin Redefining Treatment for Addiction, Recovery, and Relapse Prevention in the Psychedelic Space

 Revitalist Partners with Awakn Life Sciences as First Licensee in the United States to begin Redefining Treatment for Addiction, Recovery, and Relapse Prevention in the Psychedelic Space

REVITALIST LIFESTYLE AND WELLNESS LTD. ("Revitalist" or the "Company") (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) announces it has signed a licensing partnership agreement with Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn') to implement their KARE® protocol for those suffering from Alcohol Use Disorder seeking sustained recovery measures focused on relapse prevention.

Awakn's proprietary ketamine-assisted therapy for the treatment of Alcohol Use Disorder was developed and validated in a Phase II a/b trial, with results announced in the American Journal of Psychiatry in January 2022. The trial delivered 86% abstinence over the six-month period post treatment versus 2% pre-trial and 25% in the current standard of care.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Awakn Life Sciences Expands Commercial Operations into the U.S. - First Licensing Partnership Agreement with Revitalist

Awakn Life Sciences Expands Commercial Operations into the U.S. - First Licensing Partnership Agreement with Revitalist

Awakn enters the U.S. addiction treatment and relapse prevention market

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today it has signed a licensing partnership agreement with Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) ("Revitalist"), one of the largest publicly listed U.S. based ketamine wellness-clinic chains. The agreement will enable Revitalist to treat clients with Awakn's proprietary ketamine-assisted therapy for the treatment of AUD.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×